Cardiac effects of OPA1 protein promotion in a transgenic animal model
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0310394 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kitti Bruszt und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Medicine, University of Pecs Medical School, Pecs, Hungary. Hauptthemen laut MEDLINE: GTP Phosphohydrolases, Mice, Transgenic, Myocytes, Cardiac. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NKFIH.
Abstract (Originalsprache)
Mitochondria form a dynamic network in cells, regulated by the balance between mitochondrial fusion and fission. The inhibition of mitochondrial fission can have positive effects in acute ischemic/reperfusion injury models by preventing the fall in mitochondrial membrane potential associated with fission processes. However, inhibition of fission in chronic models is disadvantageous because it obstructs the elimination of damaged mitochondrial fragments. OPA1, in view of previous results, is a possible therapeutic target as a fusion promoter and structure stabilizer protein. We used transgenic mice in which the OMA1 cleavage sites of OPA1 were deleted. This resulted in a higher representation of L-OPA1 compared to S-OPA1. After genotyping and model validation, all animals were examined by echocardiograph on two occasions, at weeks 11 and 36. Histological samples were taken from hearts to examine mitochondrial morphology and structure remodeling. The signaling pathways related to mitochondrial dynamic processes were evaluated. Cardiomyocytes were isolated from neonatal mice to determine the efficiency of mitochondrial respiration using the SeaHorse assay method. OPA1 protein promotion has a negative effect on systolic function during aging. We confirmed that volume overload and ventricular remodeling did not manifest. The reason behind the loss of pump function might be, at least partly, due to the energy deficit caused by mitochondrial respiratory failure and damage in mitochondrial quality control pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1st Department of Medicine, University of Pecs Medical School, Pecs, Hungary.
- Szentagothai Research Centre, University of Pecs, Pecs, Hungary.
- Department of Biochemistry and Medical Chemistry, University of Pecs Medical School, Pecs, Hungary.
ORCID-Profile: Kitti Bruszt, Katalin Ordog, Eszter Vamos, Laszlo Deres
Förderung
- NKFIH
Zitieren
APA
Bruszt, K., Horvath, O., Ordog, K., Toth, S., Juhasz, K., Vamos, E., Fekete, K., Gallyas, F., Toth, K., Halmosi, R., & Deres, L. (2024). Cardiac effects of OPA1 protein promotion in a transgenic animal model. PLOS ONE. https://doi.org/10.1371/journal.pone.0310394
Vancouver
Bruszt K, Horvath O, Ordog K, Toth S, Juhasz K, Vamos E, et al. Cardiac effects of OPA1 protein promotion in a transgenic animal model. PLOS ONE. 2024. doi:10.1371/journal.pone.0310394
BibTeX
@article{Bruszt2024,
author = {Bruszt, Kitti and Horvath, Orsolya and Ordog, Katalin and Toth, Szilard and Juhasz, Kata and Vamos, Eszter and Fekete, Katalin and Gallyas, Ferenc and Toth, Kalman and Halmosi, Robert and Deres, Laszlo},
title = {Cardiac effects of OPA1 protein promotion in a transgenic animal model},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0310394}
}
EUVIMED